VERA Vera Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why VERA matters now
Vera Therapeutics, Inc. (VERA) is a US stock in Healthcare. The latest InvestLog snapshot shows $42.00 with -1.06% on the session and $3.01B in market capitalization; recent performance reads 1-month +5.53% and YTD -30.71%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-121.0M, and EPS of $-1.69. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.7%.
The latest indexable market news headline is "Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $90.00; recent insider activity includes ENRIGHT PATRICK G filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.02
P/S
0.00
EV/EBITDA
-6.95
DCF Value
$4.05
FCF Yield
-11.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-74.9%
ROA
-59.3%
ROIC
-66.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-121.0M | $-1.69 |
| Q4 2025 | $0.00 | $-91.1M | $-1.39 |
| FY 2025 | $0.00 | $-299.6M | $-4.66 |
| Q3 2025 | $0.00 | $-80.3M | $-1.26 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$80.33
Target (Median)
$90.00
Target Range
$60.00 - $91.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.95
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.